Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METVI: Methotrexate + UVB vs UVB in Progressive Vitiligo
2024-512766-34-00Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Vitiligo comparing Methotrexate + UVB TL01 with Placebo + UVB TL01 (2 arms). Primary endpoint: Change in VASI score at 8 months. Started Jul 2024; status: completed.
02
Drugs
methotrexate
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2024-512766-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512766-34-00.